Source:http://linkedlifedata.com/resource/pubmed/id/18833044
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2008-10-3
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0026-4741
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
143
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
167
|
pubmed:meshHeading |
pubmed-meshheading:18833044-Antibodies, Monoclonal,
pubmed-meshheading:18833044-Cardiomyopathy, Hypertrophic,
pubmed-meshheading:18833044-Chronic Disease,
pubmed-meshheading:18833044-Female,
pubmed-meshheading:18833044-Heart Failure,
pubmed-meshheading:18833044-Humans,
pubmed-meshheading:18833044-Middle Aged,
pubmed-meshheading:18833044-Psoriasis
|
pubmed:year |
2008
|
pubmed:articleTitle |
Safe use of efalizumab in a psoriasis patient with chronic heart failure due to hypertrophic cardiomyopathy.
|
pubmed:publicationType |
Letter,
Case Reports
|